or Try an Advanced Search...

    Technical Analysis for MNPR - Monopar Therapeutics Inc.

    Grade Last Price % Change Price Change
    C 19.00 -0.05% -0.01
    MNPR closed down 0.05 percent on Wednesday, November 20, 2024, on 8 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Up Up Up
    Historical MNPR trend table...
    Date Alert Name Type % Chg
    Multiple of Ten Bearish Other 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    NR7 Range Contraction -0.05%
    Narrow Range Bar Range Contraction -0.05%
    Stochastic Reached Overbought Strength -0.05%
    Wide Bands Range Expansion -0.05%
    Overbought Stochastic Strength -0.05%
    Boomer Buy Setup Bullish Swing Setup 2.98%
    Narrow Range Bar Range Contraction 2.98%
    Older End-of-Day Signals for MNPR ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 18 hours ago
    Down 2 % about 18 hours ago
    Down 1% about 18 hours ago
    Up 10% about 20 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    MNPR Chart by TradingView
    Basic chart:

    Profile

    Monopar Therapeutics is a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for advanced soft tissue sarcoma; and a late-stage preclinical antibody MNPR-101.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Radiation Therapy Sarcoma Head And Neck Cancer Soft Tissue Sarcoma Mucositis Radiotherapy Oral Mucositis Otorhinolaryngology

    Is MNPR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 8 Monopar Therapeutics GAAP EPS of -$0.37
    Nov 8 Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
    Oct 30 Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
    Oct 29 Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share
    Oct 29 Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
    Oct 28 Monopar Therapeutics proposes public offering of common stock
    Oct 28 Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
    Oct 28 Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Oct 26 Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week
    Oct 25 What's Going On With Monopar Therapeutics Shares Friday?
    See more MNPR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 38.5
    52 Week Low 1.3695
    Average Volume 1,571,704
    200-Day Moving Average 5.05
    50-Day Moving Average 10.09
    20-Day Moving Average 17.73
    10-Day Moving Average 17.85
    Average True Range 2.60
    RSI (14) 61.83
    ADX 58.94
    +DI 40.41
    -DI 8.68
    Chandelier Exit (Long, 3 ATRs) 30.71
    Chandelier Exit (Short, 3 ATRs) 12.29
    Upper Bollinger Bands 25.15
    Lower Bollinger Band 10.30
    Percent B (%b) 0.59
    BandWidth 83.77
    MACD Line 2.56
    MACD Signal Line 2.69
    MACD Histogram -0.13
    Fundamentals Value
    Market Cap 282.46 Million
    Num Shares 14.9 Million
    EPS -0.72
    Price-to-Earnings (P/E) Ratio -26.39
    Price-to-Sales 0.00
    Price-to-Book 0.79
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.87
    Resistance 3 (R3) 23.17 22.17 22.23
    Resistance 2 (R2) 22.17 21.19 22.03 22.01
    Resistance 1 (R1) 20.59 20.58 20.09 20.29 21.79
    Pivot Point 19.59 19.59 19.35 19.45 19.59
    Support 1 (S1) 18.01 18.61 17.51 17.71 16.21
    Support 2 (S2) 17.01 18.00 16.87 15.99
    Support 3 (S3) 15.43 17.01 15.78
    Support 4 (S4) 15.13